首页 > 最新文献

Schizophrenia Research最新文献

英文 中文
Schizophrenia and antipsychotic medications present distinct and shared gut microbial composition: A meta-analysis. 精神分裂症和抗精神病药物的肠道微生物组成既有区别又有共性:荟萃分析
IF 3.6 2区 医学 Q1 PSYCHIATRY Pub Date : 2024-10-09 DOI: 10.1016/j.schres.2024.07.053
Weirong Cheng, Mengjie Zhao, Xinyun Zhang, Xia Zhou, Jun Yan, Rui Li, Hong Shen

There are some conflicting results regarding alterations of gut microbial composition in schizophrenia (SZ), even a few meta-analysis studies have addressed this field. Ignoring of antipsychotic medication effects may cause the large heterogeneity and impact on study results. This study is a meta-analysis to systematically evaluate composition of gut microbiota in patients with SZ, to elucidate the impact of antipsychotic use and reveal distinct and shared gut bacteria in SZ and antipsychotic medications. We re-analyzed the publicly available 16S rRNA-gene amplicon datasets by a standardized pipeline in QIIME2, used the natural log of response ratios as an effect index to directly and quantitatively compare composition of gut microbiota by random-effects meta-analysis with resampling tests in Metawin, ultimately to evaluate distinct abundance of gut bacteria. A total of 19 studies with 1968 participants (1067 patients with SZ and 901 healthy controls (HCs)) were included in this meta-analysis. The alterations of alpha diversity indices occurred in SZ on antipsychotics but not in drug-naïve or -free patients, while variation of beta diversity metrics appeared in SZ regardless of antipsychotic use. After antipsychotic treatment, reversed Simpson index, decreased observed species index and significant difference of Bray-Curtis distance were observed in patients. Especially, risperidone treatment increased the Shannon and Simpson indices. Noteworthy, three differed genera, including Lactobacillus, Roseburia and Dialister, were identified in both states of antipsychotic use. This meta-analysis is to provide a novel insight that SZ and antipsychotic medications present distinct and shared gut microbial composition.

关于精神分裂症(SZ)患者肠道微生物组成的改变,存在一些相互矛盾的结果,甚至只有少数荟萃分析研究涉及这一领域。忽略抗精神病药物的影响可能会导致研究结果存在较大的异质性并对研究结果产生影响。本研究是一项荟萃分析,旨在系统评估 SZ 患者肠道微生物群的组成,阐明使用抗精神病药物的影响,并揭示 SZ 和抗精神病药物中不同和共有的肠道细菌。我们通过QIIME2的标准化流水线重新分析了可公开获得的16S rRNA基因扩增片段数据集,使用反应比的自然对数作为效应指数,通过Metawin的随机效应荟萃分析和重采样检验直接定量比较了肠道微生物群的组成,最终评估了肠道细菌的不同丰度。本次荟萃分析共纳入了 19 项研究,1968 名参与者(1067 名 SZ 患者和 901 名健康对照者)。在服用抗精神病药物的 SZ 患者中,α多样性指数发生了变化,而未服药或未服药的患者则没有这种变化;而在 SZ 患者中,无论是否服用抗精神病药物,β多样性指标都出现了变化。在使用抗精神病药物治疗后,患者的辛普森指数发生逆转,观察到的物种指数下降,布雷-柯蒂斯距离出现显著差异。尤其是利培酮治疗会增加香农指数和辛普森指数。值得注意的是,在使用抗精神病药物的两种状态下,都发现了三个不同的菌属,包括乳酸杆菌属、玫瑰糠菌属和 Dialister 菌属。这项荟萃分析提供了一种新的见解,即 SZ 和抗精神病药物呈现出独特而又共同的肠道微生物组成。
{"title":"Schizophrenia and antipsychotic medications present distinct and shared gut microbial composition: A meta-analysis.","authors":"Weirong Cheng, Mengjie Zhao, Xinyun Zhang, Xia Zhou, Jun Yan, Rui Li, Hong Shen","doi":"10.1016/j.schres.2024.07.053","DOIUrl":"https://doi.org/10.1016/j.schres.2024.07.053","url":null,"abstract":"<p><p>There are some conflicting results regarding alterations of gut microbial composition in schizophrenia (SZ), even a few meta-analysis studies have addressed this field. Ignoring of antipsychotic medication effects may cause the large heterogeneity and impact on study results. This study is a meta-analysis to systematically evaluate composition of gut microbiota in patients with SZ, to elucidate the impact of antipsychotic use and reveal distinct and shared gut bacteria in SZ and antipsychotic medications. We re-analyzed the publicly available 16S rRNA-gene amplicon datasets by a standardized pipeline in QIIME2, used the natural log of response ratios as an effect index to directly and quantitatively compare composition of gut microbiota by random-effects meta-analysis with resampling tests in Metawin, ultimately to evaluate distinct abundance of gut bacteria. A total of 19 studies with 1968 participants (1067 patients with SZ and 901 healthy controls (HCs)) were included in this meta-analysis. The alterations of alpha diversity indices occurred in SZ on antipsychotics but not in drug-naïve or -free patients, while variation of beta diversity metrics appeared in SZ regardless of antipsychotic use. After antipsychotic treatment, reversed Simpson index, decreased observed species index and significant difference of Bray-Curtis distance were observed in patients. Especially, risperidone treatment increased the Shannon and Simpson indices. Noteworthy, three differed genera, including Lactobacillus, Roseburia and Dialister, were identified in both states of antipsychotic use. This meta-analysis is to provide a novel insight that SZ and antipsychotic medications present distinct and shared gut microbial composition.</p>","PeriodicalId":21417,"journal":{"name":"Schizophrenia Research","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142401141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association of CACNA1C polymorphisms (rs1006737, rs4765905, rs2007044) with schizophrenia: A meta-analysis and trial sequential analysis. CACNA1C多态性(rs1006737、rs4765905、rs2007044)与精神分裂症的关系:荟萃分析和试验序列分析。
IF 3.6 2区 医学 Q1 PSYCHIATRY Pub Date : 2024-10-07 DOI: 10.1016/j.schres.2024.09.029
Surjyapratap Sarangi, Saurav Sharma, Suraj Kumar Nahak, Aditya K Panda

Schizophrenia is a complex neurological disorder characterized by significant impairment in the perception of reality and changes in behavior. Genetic and environmental factors influence the development of schizophrenia. CACNA1C, which encodes a subunit of a voltage-dependent calcium channel, has been associated with various neurological disorders, including schizophrenia. Several studies have been performed in different populations to explore the association of common genetic variants in the CACNA1C gene with susceptibility to the development of schizophrenia, but results remain contradictory. To draw a definitive conclusion on the association between CACNA1C polymorphisms and schizophrenia, we conducted a meta-analysis focusing on three commonly studied polymorphisms: rs1006737, rs4765905, and rs2007044. For the meta-analysis, a comprehensive literature search was performed using PubMed, Scopus, Science Direct and Google Scholar databases. Data was retrieved, and the meta-analysis was performed using CMA v4 software. The meta-analysis revealed a significant association between rs1006737 and rs2007044 and schizophrenia in the overall population, while no such association was found for rs4765905. Population-wise analysis suggested that all three polymorphisms were significantly associated with schizophrenia in the Asian population and that rs1006737 was significantly associated with schizophrenia in Europeans. We also performed a Trial Sequential Analysis (TSA), which supported our findings. Some report-based assay studies have suggested a role for these polymorphisms in schizophrenia, but further case-control studies are needed to confirm the association of rs4765905 and rs2007044 with the disorder.

精神分裂症是一种复杂的神经系统疾病,其特征是对现实的感知能力严重受损和行为发生改变。遗传和环境因素影响着精神分裂症的发展。CACNA1C 编码电压依赖性钙通道的一个亚基,它与包括精神分裂症在内的多种神经系统疾病有关。为了探讨 CACNA1C 基因中常见遗传变异与精神分裂症易感性的关系,已在不同人群中开展了多项研究,但结果仍然相互矛盾。为了就 CACNA1C 多态性与精神分裂症之间的关联得出明确结论,我们进行了一项荟萃分析,重点研究了三个常见的多态性:rs1006737、rs4765905 和 rs2007044。为了进行荟萃分析,我们使用 PubMed、Scopus、Science Direct 和 Google Scholar 数据库进行了全面的文献检索。检索到数据后,使用 CMA v4 软件进行了荟萃分析。荟萃分析表明,在总体人群中,rs1006737 和 rs2007044 与精神分裂症有显著关联,而 rs4765905 则没有发现这种关联。人群分析表明,在亚洲人群中,这三个多态性都与精神分裂症有显著关联,而在欧洲人群中,rs1006737 与精神分裂症有显著关联。我们还进行了试验序列分析(TSA),结果也支持我们的发现。一些基于报告的检测研究表明,这些多态性在精神分裂症中发挥作用,但还需要进一步的病例对照研究来证实 rs4765905 和 rs2007044 与精神分裂症的关系。
{"title":"Association of CACNA1C polymorphisms (rs1006737, rs4765905, rs2007044) with schizophrenia: A meta-analysis and trial sequential analysis.","authors":"Surjyapratap Sarangi, Saurav Sharma, Suraj Kumar Nahak, Aditya K Panda","doi":"10.1016/j.schres.2024.09.029","DOIUrl":"https://doi.org/10.1016/j.schres.2024.09.029","url":null,"abstract":"<p><p>Schizophrenia is a complex neurological disorder characterized by significant impairment in the perception of reality and changes in behavior. Genetic and environmental factors influence the development of schizophrenia. CACNA1C, which encodes a subunit of a voltage-dependent calcium channel, has been associated with various neurological disorders, including schizophrenia. Several studies have been performed in different populations to explore the association of common genetic variants in the CACNA1C gene with susceptibility to the development of schizophrenia, but results remain contradictory. To draw a definitive conclusion on the association between CACNA1C polymorphisms and schizophrenia, we conducted a meta-analysis focusing on three commonly studied polymorphisms: rs1006737, rs4765905, and rs2007044. For the meta-analysis, a comprehensive literature search was performed using PubMed, Scopus, Science Direct and Google Scholar databases. Data was retrieved, and the meta-analysis was performed using CMA v4 software. The meta-analysis revealed a significant association between rs1006737 and rs2007044 and schizophrenia in the overall population, while no such association was found for rs4765905. Population-wise analysis suggested that all three polymorphisms were significantly associated with schizophrenia in the Asian population and that rs1006737 was significantly associated with schizophrenia in Europeans. We also performed a Trial Sequential Analysis (TSA), which supported our findings. Some report-based assay studies have suggested a role for these polymorphisms in schizophrenia, but further case-control studies are needed to confirm the association of rs4765905 and rs2007044 with the disorder.</p>","PeriodicalId":21417,"journal":{"name":"Schizophrenia Research","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142392941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dyadic interaction in schizophrenia - A promising new avenue of investigation? 精神分裂症中的二元交互作用--有希望的新研究途径?
IF 3.6 2区 医学 Q1 PSYCHIATRY Pub Date : 2024-10-03 DOI: 10.1016/j.schres.2024.09.032
Michal Hajdúk, Sohee Park, Amy E Pinkham
{"title":"Dyadic interaction in schizophrenia - A promising new avenue of investigation?","authors":"Michal Hajdúk, Sohee Park, Amy E Pinkham","doi":"10.1016/j.schres.2024.09.032","DOIUrl":"10.1016/j.schres.2024.09.032","url":null,"abstract":"","PeriodicalId":21417,"journal":{"name":"Schizophrenia Research","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142375896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Aligning phenomenology and neuroscience of the basic and narrative self in schizophrenia. 将精神分裂症患者的基本自我和叙事自我的现象学与神经科学结合起来。
IF 3.6 2区 医学 Q1 PSYCHIATRY Pub Date : 2024-10-03 DOI: 10.1016/j.schres.2024.09.033
Henry R Cowan
{"title":"Aligning phenomenology and neuroscience of the basic and narrative self in schizophrenia.","authors":"Henry R Cowan","doi":"10.1016/j.schres.2024.09.033","DOIUrl":"10.1016/j.schres.2024.09.033","url":null,"abstract":"","PeriodicalId":21417,"journal":{"name":"Schizophrenia Research","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142375895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Early and later remission from clinical high risk of psychosis. A latent class and predictor analysis 临床高危精神病的早期和后期缓解。潜类和预测因子分析
IF 3.6 2区 医学 Q1 PSYCHIATRY Pub Date : 2024-10-01 DOI: 10.1016/j.schres.2024.09.024

Background

In high-risk for psychosis (CHR-P) much focus has been on the transition to psychosis. However, the desired outcome remains symptomatic remission and improved functioning as early as possible. This study aims to investigate predictors of sub-groups of remission and functional outcomes.

Material and methods

A two-year prospective follow-up study of 104 CHR-P participants recruited in Norway using systematic early detection strategies. The Structural Interview for Prodromal Syndromes (SIPS) was used to assess CHR-P. Participants were classified as remitted or non-remitted based on their symptom scores. A latent class analysis was performed on the dichotomous data to identify latent classes regarding the timing of remission. t-tests and chi-squared tests were used to assess the association between class affiliations, predictors and outcomes.

Results

The latent class analysis showed moderate fit and divided the participants into three remission classes: “poor chance of remission” (16.7 %), “later remission” (34.3 %), and “early remission” (49.0 %). The “early remission” class had the highest probability of fast and stable remission, and had better premorbid academic, and baseline and 2-year global functioning than the “later remission” class. Baseline predictors such as age, SIPS symptoms, drug use, years in school and gender were not significantly associated with remission class.

Discussion

The study's main finding is the division of CHR-P remission into “early remission” and “later remission” and predictors of class affiliation. The monthly follow-up during the first six months allowed for the detection of this division. The findings suggest the importance of considering functioning in models of remission from CHR-P.
背景在高危精神病患者(CHR-P)中,很多人都把注意力集中在向精神病的过渡上。然而,理想的结果仍然是尽早缓解症状和改善功能。本研究旨在调查症状缓解和功能改善亚组的预测因素。材料和方法:本研究采用系统的早期检测策略,对在挪威招募的104名CHR-P参与者进行了为期两年的前瞻性随访研究。采用前驱综合征结构访谈(SIPS)评估CHR-P。根据症状评分将参与者分为缓解和未缓解两类。对二分法数据进行潜类分析,以确定缓解时间的潜类。采用 t 检验和卡方检验来评估类别归属、预测因素和结果之间的关联:"缓解机会差"(16.7%)、"缓解较晚"(34.3%)和 "缓解较早"(49.0%)。与 "晚期缓解 "分级相比,"早期缓解 "分级的快速和稳定缓解概率最高,病前学习成绩、基线和 2 年的整体功能也更好。年龄、SIPS 症状、药物使用、在校年数和性别等基线预测因素与缓解等级无明显关联。 讨论 本研究的主要发现是将 CHR-P 缓解分为 "早期缓解 "和 "后期缓解",并预测了等级归属。在最初的 6 个月中,每月一次的随访可以发现这种划分。研究结果表明,在 CHR-P 缓解模型中考虑功能的重要性。
{"title":"Early and later remission from clinical high risk of psychosis. A latent class and predictor analysis","authors":"","doi":"10.1016/j.schres.2024.09.024","DOIUrl":"10.1016/j.schres.2024.09.024","url":null,"abstract":"<div><h3>Background</h3><div>In high-risk for psychosis (CHR-P) much focus has been on the transition to psychosis. However, the desired outcome remains symptomatic remission and improved functioning as early as possible. This study aims to investigate predictors of sub-groups of remission and functional outcomes.</div></div><div><h3>Material and methods</h3><div>A two-year prospective follow-up study of 104 CHR-P participants recruited in Norway using systematic early detection strategies. The Structural Interview for Prodromal Syndromes (SIPS) was used to assess CHR-P. Participants were classified as remitted or non-remitted based on their symptom scores. A latent class analysis was performed on the dichotomous data to identify latent classes regarding the timing of remission. <em>t</em>-tests and chi-squared tests were used to assess the association between class affiliations, predictors and outcomes.</div></div><div><h3>Results</h3><div>The latent class analysis showed moderate fit and divided the participants into three remission classes: “poor chance of remission” (16.7 %), “later remission” (34.3 %), and “early remission” (49.0 %). The “early remission” class had the highest probability of fast and stable remission, and had better premorbid academic, and baseline and 2-year global functioning than the “later remission” class. Baseline predictors such as age, SIPS symptoms, drug use, years in school and gender were not significantly associated with remission class.</div></div><div><h3>Discussion</h3><div>The study's main finding is the division of CHR-P remission into “early remission” and “later remission” and predictors of class affiliation. The monthly follow-up during the first six months allowed for the detection of this division. The findings suggest the importance of considering functioning in models of remission from CHR-P.</div></div>","PeriodicalId":21417,"journal":{"name":"Schizophrenia Research","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142358106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effects of acute smoking abstinence among people with schizophrenia: A systematic review and meta-analysis of laboratory studies 精神分裂症患者急性戒烟的效果:实验室研究的系统回顾和荟萃分析
IF 3.6 2区 医学 Q1 PSYCHIATRY Pub Date : 2024-09-30 DOI: 10.1016/j.schres.2024.09.025

Background

Smoking rates in schizophrenia are exceptionally high; however, cessation rates remain low with limited research on effective interventions. A critical component of intervention development is identifying the effects of abstinence that are most salient and therefore may contribute to lapse and relapse.

Objectives

We conducted a systematic review and meta-analysis of controlled laboratory studies investigating acute smoking abstinence effects among people with schizophrenia and schizoaffective disorder.

Methods

This review is reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. OVID (MEDLINE, EMBASE, PsycINFO) and PubMed databases were searched from inception until November 2023.

Results

We identified (k = 16) articles meeting inclusion criteria; all assessed smoking abstinence (ranging 2–120 h). Acute abstinence resulted in large increases in reward-oriented craving and moderate increases in relief-oriented craving; these effects were greater in studies with longer abstinence duration (high certainty). We also observed significant increases in negative affect and global withdrawal symptoms, as well as memory disruption (moderate certainty). Qualitative synthesis suggests restlessness, irritability, anxiety, and visuospatial working memory may be additionally impacted. Findings with respect to negative symptoms and movement were mixed.

Conclusions

Reward-oriented craving may constitute a key target of smoking cessation interventions for people with schizophrenia. In addition, identification of pharmacological and psychosocial interventions that address abstinence-induced changes in relief-oriented craving, memory, negative affect, restlessness, irritability, and anxiety may strengthen treatment outcomes.
背景精神分裂症患者的吸烟率极高;然而,戒烟率仍然很低,有效干预措施的研究也很有限。我们对精神分裂症和分裂情感障碍患者急性戒烟效果的实验室对照研究进行了系统综述和荟萃分析。检索了OVID(MEDLINE、EMBASE、PsycINFO)和PubMed数据库,检索时间从开始到2023年11月。结果我们发现(k = 16)篇文章符合纳入标准;所有文章都对戒烟(2-120小时不等)进行了评估。急性戒烟导致以回报为导向的渴求大幅增加,以解脱为导向的渴求适度增加;在戒烟持续时间较长的研究中,这些影响更大(高度确定性)。我们还观察到消极情绪和全面戒断症状以及记忆中断的明显增加(中等确定性)。定性综合分析表明,烦躁不安、易怒、焦虑和视觉空间工作记忆可能会受到额外影响。结论以奖赏为导向的渴求可能是精神分裂症患者戒烟干预的关键目标。此外,针对戒烟引起的缓解型渴求、记忆、负性情绪、烦躁不安、易激惹和焦虑的变化,确定药物和心理干预措施可能会加强治疗效果。
{"title":"Effects of acute smoking abstinence among people with schizophrenia: A systematic review and meta-analysis of laboratory studies","authors":"","doi":"10.1016/j.schres.2024.09.025","DOIUrl":"10.1016/j.schres.2024.09.025","url":null,"abstract":"<div><h3>Background</h3><div>Smoking rates in schizophrenia are exceptionally high; however, cessation rates remain low with limited research on effective interventions. A critical component of intervention development is identifying the effects of abstinence that are most salient and therefore may contribute to lapse and relapse.</div></div><div><h3>Objectives</h3><div>We conducted a systematic review and meta-analysis of controlled laboratory studies investigating acute smoking abstinence effects among people with schizophrenia and schizoaffective disorder.</div></div><div><h3>Methods</h3><div>This review is reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. OVID (MEDLINE, EMBASE, PsycINFO) and PubMed databases were searched from inception until November 2023.</div></div><div><h3>Results</h3><div>We identified (k = 16) articles meeting inclusion criteria; all assessed smoking abstinence (ranging 2–120 h). Acute abstinence resulted in large increases in reward-oriented craving and moderate increases in relief-oriented craving; these effects were greater in studies with longer abstinence duration (high certainty). We also observed significant increases in negative affect and global withdrawal symptoms, as well as memory disruption (moderate certainty). Qualitative synthesis suggests restlessness, irritability, anxiety, and visuospatial working memory may be additionally impacted. Findings with respect to negative symptoms and movement were mixed.</div></div><div><h3>Conclusions</h3><div>Reward-oriented craving may constitute a key target of smoking cessation interventions for people with schizophrenia. In addition, identification of pharmacological and psychosocial interventions that address abstinence-induced changes in relief-oriented craving, memory, negative affect, restlessness, irritability, and anxiety may strengthen treatment outcomes.</div></div>","PeriodicalId":21417,"journal":{"name":"Schizophrenia Research","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142358163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A network meta-analysis of KarXT and commonly used pharmacological interventions for schizophrenia 对 KarXT 和常用药物干预精神分裂症的网络荟萃分析。
IF 3.6 2区 医学 Q1 PSYCHIATRY Pub Date : 2024-09-29 DOI: 10.1016/j.schres.2024.09.023

Background

Dopaminergic antipsychotics for schizophrenia have modest effects on symptoms and can cause important side effects. KarXT is an investigational drug for schizophrenia with a novel mechanism targeting muscarinic receptors that may limit these side effects.

Methods

We conducted a systematic review and Bayesian random-effects network meta-analyses of short-term RCTs (3–8 weeks) that enrolled adults with schizophrenia. We compared KarXT to aripiprazole, risperidone, and olanzapine. We sought evidence for symptoms (Positive and Negative Symptoms Scale [PANSS]), weight gain, and all-cause discontinuation.

Results

We included 33 trials with 7193 participants. For total, positive, and negative symptoms, KarXT and the three antipsychotics were significantly more efficacious than placebo (mean difference [MD] vs placebo range for total symptoms: −10.67 to −8.05; positive symptoms: −3.46 to −2.53; negative symptoms: −1.99 to −1.44) but not significantly different from each other. KarXT was ranked as least likely to lead to weight gain. This was significant versus risperidone (−2.06 kg; 95 % CrI: −3.28, −0.87) and olanzapine (−2.86 kg; 95 % CrI: −3.97, −1.82). However, KarXT was ranked highest for all-cause discontinuation. This was significant versus risperidone (RR: 0.64; 95 % CrI: 0.46, 0.89) and olanzapine (RR: 0.6; 95 % CrI: 0.44, 0.83).

Conclusions

KarXT and commonly used antipsychotics were more efficacious than placebo at reducing symptoms, but there were no clear differences in short-term efficacy among the active interventions. KarXT was less likely to cause weight gain, an important outcome for those with schizophrenia; short-term data do not permit evaluation of the risk for tardive dyskinesia. Long-term data are needed.
背景:治疗精神分裂症的多巴胺能抗精神病药物对症状的影响不大,但会引起严重的副作用。KarXT是一种治疗精神分裂症的在研药物,其针对毒蕈碱受体的新机制可能会限制这些副作用:我们对纳入成年精神分裂症患者的短期 RCT(3-8 周)进行了系统回顾和贝叶斯随机效应网络荟萃分析。我们将KarXT与阿立哌唑、利培酮和奥氮平进行了比较。我们寻求有关症状(阳性和阴性症状量表 [PANSS])、体重增加和全因停药的证据:我们纳入了 33 项试验,共有 7193 名参与者。在总症状、阳性症状和阴性症状方面,KarXT和三种抗精神病药物的疗效明显优于安慰剂(总症状的平均差[MD]与安慰剂的比较范围为-10.67至-8.67):总症状:-10.67 至 -8.05;阳性症状:-3.46 至 -2.05):积极症状:-3.46 至 -2.53;消极症状:-1.99 至 -1.44):KarXT与安慰剂的平均差异[MD]范围为:总症状:-10.67至-8.05;阳性症状:-3.46至-2.53;阴性症状:-1.99至-1.44),但相互之间无显著差异。KarXT 被评为最不可能导致体重增加的药物。这一点与利培酮(-2.06 千克;95 % CrI:-3.28,-0.87)和奥氮平(-2.86 千克;95 % CrI:-3.97,-1.82)相比具有显著性差异。然而,KarXT 的全因停药率最高。这与利培酮(RR:0.64;95 % CrI:0.46,0.89)和奥氮平(RR:0.6;95 % CrI:0.44,0.83)相比具有显著性差异:结论:KarXT和常用抗精神病药物在减轻症状方面的疗效优于安慰剂,但积极干预措施之间的短期疗效没有明显差异。KarXT不太可能导致体重增加,而体重增加对精神分裂症患者来说是一个重要的结果;短期数据不允许对迟发性运动障碍的风险进行评估。还需要长期数据。
{"title":"A network meta-analysis of KarXT and commonly used pharmacological interventions for schizophrenia","authors":"","doi":"10.1016/j.schres.2024.09.023","DOIUrl":"10.1016/j.schres.2024.09.023","url":null,"abstract":"<div><h3>Background</h3><div>Dopaminergic antipsychotics for schizophrenia have modest effects on symptoms and can cause important side effects. KarXT is an investigational drug for schizophrenia with a novel mechanism targeting muscarinic receptors that may limit these side effects.</div></div><div><h3>Methods</h3><div>We conducted a systematic review and Bayesian random-effects network meta-analyses of short-term RCTs (3–8 weeks) that enrolled adults with schizophrenia. We compared KarXT to aripiprazole, risperidone, and olanzapine. We sought evidence for symptoms (Positive and Negative Symptoms Scale [PANSS]), weight gain, and all-cause discontinuation.</div></div><div><h3>Results</h3><div>We included 33 trials with 7193 participants. For total, positive, and negative symptoms, KarXT and the three antipsychotics were significantly more efficacious than placebo (mean difference [MD] vs placebo range for total symptoms: −10.67 to −8.05; positive symptoms: −3.46 to −2.53; negative symptoms: −1.99 to −1.44) but not significantly different from each other. KarXT was ranked as least likely to lead to weight gain. This was significant versus risperidone (−2.06 kg; 95 % CrI: −3.28, −0.87) and olanzapine (−2.86 kg; 95 % CrI: −3.97, −1.82). However, KarXT was ranked highest for all-cause discontinuation. This was significant versus risperidone (RR: 0.64; 95 % CrI: 0.46, 0.89) and olanzapine (RR: 0.6; 95 % CrI: 0.44, 0.83).</div></div><div><h3>Conclusions</h3><div>KarXT and commonly used antipsychotics were more efficacious than placebo at reducing symptoms, but there were no clear differences in short-term efficacy among the active interventions. KarXT was less likely to cause weight gain, an important outcome for those with schizophrenia; short-term data do not permit evaluation of the risk for tardive dyskinesia. Long-term data are needed.</div></div>","PeriodicalId":21417,"journal":{"name":"Schizophrenia Research","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142353040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Schizophrenia spectrum disorders in children and adolescents: Clinical, phenomenological, diagnostic, and prognostic features across subtypes 儿童和青少年精神分裂症谱系障碍:各亚型的临床、现象学、诊断和预后特征
IF 3.6 2区 医学 Q1 PSYCHIATRY Pub Date : 2024-09-27 DOI: 10.1016/j.schres.2024.09.019
Schizophrenia spectrum disorders (SSD) typically have a diagnostically recognizable onset in young adulthood, yet it is not unusual that help-seeking due to initial SSD-related clinical manifestations emerge in earlier developmental phases, such as childhood and adolescence. Varieties of SSD manifestations in children and adolescents can be distinguished according to variations in clinical expressivity, severity and timing (i.e. developmental stage). Some individuals may reach the full clinical threshold for a diagnosis of schizophrenia according to the same descriptive diagnostic criteria used for adults, and in this case, it's possible to distinguish a pre-pubertal onset in childhood (aka Very Early Onset Schizophrenia, VEOS) and a post-pubertal onset in adolescence (aka Early Onset Schizophrenia, EOS). Other individuals may not reach such clinically overt diagnostic threshold but nonetheless present Childhood Schizotypal Disorder (CSD) or a Clinical High-Risk for Psychosis (CHRP). While EOS is clinically more similar to the canonical adult-onset presentation, the other 3 subgroups (i.e. VEOS, CSD, CHRP) present more nuances and specific clinical characteristics, which require ad-hoc developmental and phenomenological considerations for appropriate differential diagnosis and prognosis. Therefore, current scoping review intends to saturate such knowledge gap with respect to early SSD-phenotypes.
精神分裂症谱系障碍(SSD)在诊断上通常在青年时期发病,但在较早的发育阶段,如儿童和青少年时期,因最初的 SSD 相关临床表现而寻求帮助的情况并不少见。根据临床表现、严重程度和时间(即发育阶段)的不同,可以区分儿童和青少年的各种 SSD 表现。根据与成人相同的描述性诊断标准,有些人可能达到了精神分裂症诊断的临床阈值,在这种情况下,可以区分青春期前发病的儿童期(又称极早发精神分裂症,VEOS)和青春期后发病的青少年期(又称早发精神分裂症,EOS)。还有一些人可能没有达到这种临床诊断阈值,但却表现为儿童分裂型障碍(CSD)或临床精神病高危人群(CHRP)。虽然 EOS 在临床上更类似于典型的成人发病表现,但其他 3 个亚群(即 VEOS、CSD、CHRP)表现出更多细微差别和特定的临床特征,这就需要在适当的鉴别诊断和预后方面对其发展和现象进行专门考虑。因此,本次范围界定综述旨在填补有关早期 SSD 表型的知识空白。
{"title":"Schizophrenia spectrum disorders in children and adolescents: Clinical, phenomenological, diagnostic, and prognostic features across subtypes","authors":"","doi":"10.1016/j.schres.2024.09.019","DOIUrl":"10.1016/j.schres.2024.09.019","url":null,"abstract":"<div><div>Schizophrenia spectrum disorders (SSD) typically have a diagnostically recognizable onset in young adulthood, yet it is not unusual that help-seeking due to initial SSD-related clinical manifestations emerge in earlier developmental phases, such as childhood and adolescence. Varieties of SSD manifestations in children and adolescents can be distinguished according to variations in clinical expressivity, severity and timing (i.e. developmental stage). Some individuals may reach the full clinical threshold for a diagnosis of schizophrenia according to the same descriptive diagnostic criteria used for adults, and in this case, it's possible to distinguish a pre-pubertal onset in childhood (aka Very Early Onset Schizophrenia, VEOS) and a post-pubertal onset in adolescence (aka Early Onset Schizophrenia, EOS). Other individuals may not reach such clinically overt diagnostic threshold but nonetheless present Childhood Schizotypal Disorder (CSD) or a Clinical High-Risk for Psychosis (CHR<img>P). While EOS is clinically more similar to the canonical adult-onset presentation, the other 3 subgroups (i.e. VEOS, CSD, CHR<img>P) present more nuances and specific clinical characteristics, which require ad-hoc developmental and phenomenological considerations for appropriate differential diagnosis and prognosis. Therefore, current scoping review intends to saturate such knowledge gap with respect to early SSD-phenotypes.</div></div>","PeriodicalId":21417,"journal":{"name":"Schizophrenia Research","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142324115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Winter birth: A factor of poor functional outcome in a Swiss early psychosis cohort 冬季出生:瑞士早期精神病队列中功能不良的一个因素
IF 3.6 2区 医学 Q1 PSYCHIATRY Pub Date : 2024-09-27 DOI: 10.1016/j.schres.2024.09.022

Objective

Winter birth has consistently been identified as a risk factor for schizophrenia. This study aimed to determine whether individuals born during this season are also at higher risk for early psychosis and whether this is associated with distinct functional and clinical outcomes.

Methods

We conducted a prospective study on 222 patients during their early phase of psychosis in Switzerland, nested in the Treatment and Early Intervention in Psychosis (TIPP) cohort. We compared the birth trimesters of these patients with those of the general Swiss population. Additionally, we evaluated the Global Assessment of Functioning scale (GAF) and the Positive and Negative Syndrome Scale (PANSS) scores among patients born in winter (January to March) versus those born during the rest of the year during a three-year follow-up period.

Results

A significantly higher proportion of patients experiencing early psychosis were born in winter compared to the general Swiss population. Patients born in winter had significantly lower GAF scores at 6 months, 24 months, and 36 months of follow-up, compared to patients born during the rest of the year. They also manifested fewer positive symptoms, as indicated by the PANSS positive subscale.

Conclusion

Birth in winter appears to be associated with a lower functional outcome and potentially distinct symptomatology in the early phase of psychosis.
目的 冬季出生一直被认为是精神分裂症的一个危险因素。本研究旨在确定在这个季节出生的人是否也有更高的早期精神病风险,以及这是否与不同的功能和临床结果有关。方法我们对瑞士 222 名处于精神病早期阶段的患者进行了一项前瞻性研究,这些患者嵌套在精神病治疗和早期干预(TIPP)队列中。我们将这些患者的出生三个月与瑞士普通人群的出生三个月进行了比较。此外,在为期三年的随访期间,我们还评估了冬季(1 月至 3 月)出生的患者与其他时间出生的患者的全球功能评估量表(GAF)和阳性与阴性综合征量表(PANSS)得分。与其他季节出生的患者相比,冬季出生的患者在6个月、24个月和36个月的随访中GAF评分明显较低。结论:冬季出生的患者似乎与较低的功能预后和早期精神病的潜在症状有关。
{"title":"Winter birth: A factor of poor functional outcome in a Swiss early psychosis cohort","authors":"","doi":"10.1016/j.schres.2024.09.022","DOIUrl":"10.1016/j.schres.2024.09.022","url":null,"abstract":"<div><h3>Objective</h3><div>Winter birth has consistently been identified as a risk factor for schizophrenia. This study aimed to determine whether individuals born during this season are also at higher risk for early psychosis and whether this is associated with distinct functional and clinical outcomes.</div></div><div><h3>Methods</h3><div>We conducted a prospective study on 222 patients during their early phase of psychosis in Switzerland, nested in the Treatment and Early Intervention in Psychosis (TIPP) cohort. We compared the birth trimesters of these patients with those of the general Swiss population. Additionally, we evaluated the Global Assessment of Functioning scale (GAF) and the Positive and Negative Syndrome Scale (PANSS) scores among patients born in winter (January to March) versus those born during the rest of the year during a three-year follow-up period.</div></div><div><h3>Results</h3><div>A significantly higher proportion of patients experiencing early psychosis were born in winter compared to the general Swiss population. Patients born in winter had significantly lower GAF scores at 6 months, 24 months, and 36 months of follow-up, compared to patients born during the rest of the year. They also manifested fewer positive symptoms, as indicated by the PANSS positive subscale.</div></div><div><h3>Conclusion</h3><div>Birth in winter appears to be associated with a lower functional outcome and potentially distinct symptomatology in the early phase of psychosis.</div></div>","PeriodicalId":21417,"journal":{"name":"Schizophrenia Research","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142327029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sleep quality, psychological resilience, family resilience, social support, and mental disability in patients with chronic schizophrenia: A cross-sectional study 慢性精神分裂症患者的睡眠质量、心理复原力、家庭复原力、社会支持和精神残疾:横断面研究
IF 3.6 2区 医学 Q1 PSYCHIATRY Pub Date : 2024-09-27 DOI: 10.1016/j.schres.2024.09.020
After the remission of psychotic symptoms in patients with chronic schizophrenia, a persistently high rate of disability suggests potential influences from socio-ecological factors. This study aimed to explore the complex relationships between socioecological factors, including sleep quality, psychological resilience, family resilience, and social support, and the severity of psychiatric disability in patients with chronic schizophrenia. Employing a cross-sectional design, the study involved 188 individuals with chronic schizophrenia. Disability was measured using the World Health Organization Disability Assessment Schedule 2.0 (WHO-DAS 2.0), while social support, family resilience, psychological resilience, and sleep quality were assessed using the Social Support Rating Scale (SSRS), Family Hardiness Index (FHI), Connor-Davidson Resilience Scale (CD-RISC), and Pittsburgh Sleep Quality Index (PSQI), respectively. LASSO regression and structural equation modeling (SEM) analyses were conducted to identify predictive factors and their interrelationships. The mean WHO-DAS 2.0 score of 72.91 ± 14.04 indicated substantial difficulties in daily activities, necessitating comprehensive support among participants. LASSO regression identified frequent disease relapses, low education levels, and poor sleep quality as risk factors for disability, whereas strong social support, family resilience, and individual resilience emerged as protective factors against disability. SEM demonstrated that the enhancement of family and individual resilience by social support contributes to the mitigation of disability. The study underscores the critical roles of social support, family resilience, and individual psychological resilience in reducing disability in patients with chronic schizophrenia, suggesting that interventions targeting these factors may improve rehabilitation outcomes.
慢性精神分裂症患者的精神症状缓解后,其残疾率仍居高不下,这表明社会生态因素可能对其产生影响。本研究旨在探讨睡眠质量、心理复原力、家庭复原力和社会支持等社会生态因素与慢性精神分裂症患者精神残疾严重程度之间的复杂关系。研究采用横断面设计,共涉及 188 名慢性精神分裂症患者。残疾程度采用世界卫生组织残疾评估表 2.0(WHO-DAS 2.0)进行测量,而社会支持、家庭复原力、心理复原力和睡眠质量则分别采用社会支持评定量表(SSRS)、家庭坚韧性指数(FHI)、康纳-戴维森复原力量表(CD-RISC)和匹兹堡睡眠质量指数(PSQI)进行评估。通过 LASSO 回归和结构方程模型(SEM)分析,确定了预测因素及其相互关系。WHO-DAS 2.0 的平均得分为 72.91 ± 14.04,这表明参与者在日常活动中存在很大困难,需要全面的支持。LASSO 回归发现,疾病频繁复发、教育水平低和睡眠质量差是导致残疾的风险因素,而强大的社会支持、家庭复原力和个人复原力则是防止残疾的保护因素。SEM 表明,社会支持对家庭和个人复原力的增强有助于减轻残疾。该研究强调了社会支持、家庭复原力和个人心理复原力对减少慢性精神分裂症患者残疾的关键作用,表明针对这些因素的干预措施可改善康复效果。
{"title":"Sleep quality, psychological resilience, family resilience, social support, and mental disability in patients with chronic schizophrenia: A cross-sectional study","authors":"","doi":"10.1016/j.schres.2024.09.020","DOIUrl":"10.1016/j.schres.2024.09.020","url":null,"abstract":"<div><div>After the remission of psychotic symptoms in patients with chronic schizophrenia, a persistently high rate of disability suggests potential influences from socio-ecological factors. This study aimed to explore the complex relationships between socioecological factors, including sleep quality, psychological resilience, family resilience, and social support, and the severity of psychiatric disability in patients with chronic schizophrenia. Employing a cross-sectional design, the study involved 188 individuals with chronic schizophrenia. Disability was measured using the World Health Organization Disability Assessment Schedule 2.0 (WHO-DAS 2.0), while social support, family resilience, psychological resilience, and sleep quality were assessed using the Social Support Rating Scale (SSRS), Family Hardiness Index (FHI), Connor-Davidson Resilience Scale (CD-RISC), and Pittsburgh Sleep Quality Index (PSQI), respectively. LASSO regression and structural equation modeling (SEM) analyses were conducted to identify predictive factors and their interrelationships. The mean WHO-DAS 2.0 score of 72.91 ± 14.04 indicated substantial difficulties in daily activities, necessitating comprehensive support among participants. LASSO regression identified frequent disease relapses, low education levels, and poor sleep quality as risk factors for disability, whereas strong social support, family resilience, and individual resilience emerged as protective factors against disability. SEM demonstrated that the enhancement of family and individual resilience by social support contributes to the mitigation of disability. The study underscores the critical roles of social support, family resilience, and individual psychological resilience in reducing disability in patients with chronic schizophrenia, suggesting that interventions targeting these factors may improve rehabilitation outcomes.</div></div>","PeriodicalId":21417,"journal":{"name":"Schizophrenia Research","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142327028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Schizophrenia Research
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1